主动脉反流 – Medxy AI

Myocardial Fibrosis and Reverse Remodeling After Valve Replacement in Chronic Aortic Regurgitation: Advances and Clinical Implications

By MedXY 08/28/2026

This review synthesizes current evidence on myocardial fibrosis and ventricular remodeling after AVR in chronic AR, highlighting imaging biomarkers, remodeling patterns, and functional outcomes relevant to clinical practice.

Cardiology Clinical Updates news

Subvalvular Aortic Stenosis in Adults: Clinical Course and Long-Term Outcomes

By MedXY 08/11/2026

This review synthesizes recent evidence on adult subvalvular aortic stenosis, highlighting long-term clinical outcomes, disease progression, and implications for management and follow-up strategy.

Cardiology news

Sex-Specific Risk Thresholds in Aortic Regurgitation: Challenging the One-Size-Fits-All Approach to LV Remodeling

By MedXY 03/26/2026

A multicenter study reveals that women with moderate-severe aortic regurgitation face higher mortality risk at lower ventricular volumes than men. Findings suggest current guidelines may require revision to include sex-specific volumetric thresholds and lower linear diameter cutoffs to optimize surgical timing.

Cardiology news

Sex-Specific Risk Stratification in Aortic Regurgitation: Moving Beyond One-Size-Fits-All Thresholds

By MedXY 03/21/2026

New evidence suggests that current guidelines for aortic regurgitation may overlook sex-specific risks. A recent study proposes lower surgical thresholds for both sexes and distinct volumetric cutoffs (40 mL/m² for women, 45 mL/m² for men) to improve survival outcomes and precision in cardiac care.

Cardiology news

Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

By MedXY 03/14/2026

A large-scale multicenter study demonstrates that moderate mixed aortic valve disease (MAVD) carries a mortality risk comparable to severe aortic stenosis when symptoms or left ventricular dysfunction are present, challenging current guideline-based management for these patients.

Cardiology news

Pioneer Valve Demonstrates Mid-Term Efficacy for Pure Aortic Regurgitation in Multicenter Trial

By MedXY 01/17/2026

The prospective Pioneer Trial demonstrates that a novel self-expanding TAVR device achieves 99.1% technical success and low mortality (2.7%) at one year for high-risk patients with pure aortic regurgitation, providing a safe, hemodynamically stable alternative to surgery.